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 Letter to the Editor 
on CPAP therapy were recruited. Eleven were randomised to con-
tinue on CPAP for 2 weeks as the control, and 12 were randomised 
to receive sham CPAP for 2 weeks, i.e. CPAP withdrawal, in a dou-
ble-blinded manner  [6] . Participants were well matched for age 
[CPAP mean 59 (SD 7.8) years old, sham CPAP 61.1 (8.9) years 
old], original OSA severity (established by having withdrawn 
CPAP for 4 nights prior to the actual trial to prove that their OSA 
did indeed return), oxygen desaturation index (ODI) [CPAP 53.1 
(14.5), sham CPAP 54.6 (22.0)] and BMI [CPAP 36.8 (7.4), sham 
CPAP 36.9 (7.5)]. CPAP withdrawal led to a rise in ODI of >4% 
from 3.1 (3.2)/h to 43.0 (24.2)/h, whereas the ODI in the control 
group remained unchanged as expected.
 MVs were measured by flow cytometry, as described previous-
ly  [7] . Procoagulant MVs were determined using annexin V bind-
ing, platelet MVs were identified by CD31 and CD41 dual positiv-
ity or CD61 expression, and leucocyte MVs were stained with 
CD45. The analyses were carried out blind of the group allocation.
 There was no significant difference between the baseline levels 
of MVs in the CPAP versus sham CPAP groups. We found sig-
nificant elevations in procoagulant MVs (p = 0.043) and platelet-
derived MVs (CD31+CD41+ p = 0.033, CD61+ p = 0.032) in the 
CPAP withdrawal group, which were not seen in the participants 
that continued on CPAP therapy. For procoagulant and platelet-
derived MVs there was a significant difference in the treatment 
effect between the patient groups. For leucocyte-derived MVs 
there was a trend towards a greater increase in the CPAP with-
drawal group; however, the change was not significantly different 
between the two groups ( table 1 ).
 In contrast to our previous study we found significant eleva-
tions in procoagulant and platelet-derived MVs in individuals 
withdrawn from effective CPAP therapy for 2 weeks, when com-
pared to matched patients continuing on CPAP therapy. This dif-
ference may be due to the cohort of participants in the current 
study having higher BMIs and a greater increase in ODI during 
CPAP withdrawal, when compared to the previous study. Untreat-
ed OSA patients are known to have elevated levels of platelet MVs 
and levels correlate with OSA severity  [4, 8, 9] . Elevated levels of 
platelet MVs may play a role in the development of the coagula-
 In 2013 we reported that in patients with obstructive sleep ap-
noea (OSA), withdrawing their continuous positive airway pres-
sure (CPAP) therapy for 2 weeks led to a significant increase in 
endothelial cell-derived microvesicles (MVs)  [1] . Several other 
studies have found that the initiation of CPAP therapy in patients 
with OSA leads to a fall in endothelial  [2, 3] and platelet  [4, 5] MVs, 
but there have been no further studies investigating the impact of 
CPAP withdrawal in patients established on therapy, which pro-
vides a more robust experimental protocol. Therefore, in this fur-
ther exploratory study we have examined the impact of CPAP 
withdrawal on other subtypes of MVs.
 Fourteen of the patients in this study were included in a previ-
ously published study, where the primary outcome measure was a 
marker of oxidative stress (PMID 26022961) and this publication 
includes the full protocol. A total of 23 OSA patients established 
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 Table 1.  Baseline and 2-week levels of circulating MVs by mean (SD)
CPAP (n = 11) Sham CPAP (n = 12)  Treatment effect (delta change)
baseline 2 weeks p value baseline 2 weeks p value me an (95% CI) p value
Annexin V+ procoagulant MVs 2,576 (412) 2,410 (377) 0.724 2,001 (658) 3,264 (963) 0.043* +1,489 (239 to 2,739) 0.019*
CD31+CD41+ platelet MVs 2,331 (416) 2,191 (362) 0.760 1,808 (678) 3,030 (934) 0.033* +1,439 (344 to 2,555) 0.020*
CD61+ platelet MVs 2,373 (426) 2,208 (353) 0.699 1,847 (681) 3,093 (945) 0.032* +1,480 (363 to 2,597) 0.019*
CD45+ leucocyte MVs 15 (2) 18 (3) 0.186 13 (2) 21 (4) 0.018* +10.5 (–1.1 to 16.1) 0.241
 Treatment effect shows the difference between groups in delta change of microvesicle (MV) levels. * p < 0.05.
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tion, inflammatory and atherogenic processes potentially provid-
ing a link between OSA and cardiovascular disease. The findings 
that successful CPAP therapy reduces platelet MV levels, and the 
withdrawal of this CPAP leads to an elevation, as shown in the cur-
rent study, suggests that platelet MVs are a potential biomarker of 
an OSA-induced effect on atherogenic processes, and that therapy 
can reduce them.
 Leucocyte MVs have also been shown to be elevated in untreat-
ed OSA patients  [8] and a correlation was noted with the apnoea-
hypopnoea index in children with OSA  [9] . Leucocyte MVs are 
present at high levels in patients with atherosclerosis and diabetes, 
and they are thought to be involved in the processes of inflamma-
tion, thrombosis and endothelial dysfunction  [10] .
 Although there is a paucity of robust randomised and con-
trolled studies and conflicting data, CPAP therapy and the conse-
quent reduction in intermittent hypoxia and catecholamine levels 
may reduce platelet activation  [11] and inflammation  [12] , pro-
cesses thought to trigger MV release, thus potentially explaining 
the changes in circulating MVs found with the commencing or 
withdrawal of CPAP. Thus, CPAP therapy may reduce the risk of 
patients developing co-morbidities such as cardiovascular disease 
 [13] , and if this link is firmly established, then lowered circulating 
MVs may be a part of the explanation. However, the true causal 
nature of MVs in the pathogenesis of vascular co-morbidities 
linked to OSA requires further investigation.
 
 References 
 1 Ayers L, Stoewhas AC, Ferry B, Stradling J, Kohler M: Elevated levels of 
endothelial cell-derived microparticles following short-term withdrawal 
of continuous positive airway pressure in patients with obstructive sleep 
apnea: data from a randomized controlled trial. Respiration 2013; 85: 
 478–485. 
 2 Yun CH, Jung KH, Chu K, Kim SH, Ji KH, Park HK, Kim HC, Lee ST, 
Lee SK, Roh JK: Increased circulating endothelial microparticles and ca-
rotid atherosclerosis in obstructive sleep apnea. J Clin Neurol 2010; 6: 
 89–98. 
 3 Jelic S, Lederer DJ, Adams T, Padeletti M, Colombo PC, Factor P, Le 
Jemtel TH: Endothelial repair capacity and apoptosis are inversely re-
lated in obstructive sleep apnea. Vasc Health Risk Manag 2009; 5: 909–
920. 
 4 Maruyama K, Morishita E, Sekiya A, Omote M, Kadono T, Asakura H, 
Hashimoto M, Kobayashi M, Nakatsumi Y, Takada S, Ohtake S: Plasma 
levels of platelet-derived microparticles in patients with obstructive sleep 
apnea syndrome. J Atheroscler Thromb 2012; 19: 98–104. 
 5 Munoz-Hernandez R, Vallejo-Vaz AJ, Sanchez Armengol A, Moreno-
Luna R, Caballero-Eraso C, Macher HC, Villar J, Merino AM, Castell J, 
Capote F, Stiefel P: Obstructive sleep apnoea syndrome, endothelial 
function and markers of endothelialization. Changes after CPAP. PLoS 
One 2015; 10:e0122091. 
 6 Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson 
C, Stradling JR, Davies RJ: Ambulatory blood pressure after therapeutic 
and subtherapeutic nasal continuous positive airway pressure for ob-
structive sleep apnoea: a randomised parallel trial. Lancet 2002; 359: 204–
210. 
 7 Ayers L, Kohler M, Harrison P, Sargent I, Dragovic R, Schaap M, Nieuw-
land R, Brooks SA, Ferry B: Measurement of circulating cell-derived mi-
croparticles by flow cytometry: sources of variability within the assay. 
Thromb Res 2011; 127: 370–377. 
 8 Ayers L, Ferry B, Craig S, Nicoll D, Stradling JR, Kohler M: Circulating 
cell-derived microparticles in patients with minimally symptomatic ob-
structive sleep apnoea. Eur Respir J 2009; 33: 574–580. 
 9 Kim J, Bhattacharjee R, Kheirandish-Gozal L, Spruyt K, Gozal D: Circu-
lating microparticles in children with sleep disordered breathing. Chest 
2011; 140: 408–417. 
 10 Angelillo-Scherrer A: Leukocyte-derived microparticles in vascular ho-
meostasis. Circ Res 2012; 110: 356–369. 
 11 Akinnusi ME, Paasch LL, Szarpa KR, Wallace PK, El Solh AA: Impact of 
nasal continuous positive airway pressure therapy on markers of platelet 
activation in patients with obstructive sleep apnea. Respiration 2009; 77: 
 25–31. 
 12 Hatipoglu U, Rubinstein I: Inflammation and obstructive sleep apnea 
syndrome pathogenesis: a working hypothesis. Respiration 2003; 70: 665–
671. 
 13 McNicholas WT: Cardiovascular outcomes of CPAP therapy in obstruc-
tive sleep apnea syndrome. Am J Physiol Regul Integr Comp Physiol 
2007; 293:R1666–R1670. 
 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
58
 - 
1/
19
/2
01
7 
9:
38
:3
2 
AM
